Paracetamol effectiveness, safety and blood level monitoring during patent ductus arteriosus closure: A case series

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 27, Issue 16, 2014, Pages 1719-1721

  Kessel, Irena ^a,b   Waisman, Dan ^a,b   Lavie Nevo, Karen ^a,b   Golzman, Marcelo ^a,b   Lorber, Avraham ^b,c   Rotschild, Avi ^a,b  

^a CARMEL MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c MEYER CHILDREN S HOSPITAL   (Israel)

Author keywords

Blood level; Closure; Paracetamol; Patent ductus arteriosus

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; ANALGESIC AGENT;

ANALGESIA; ARTICLE; ARTIFICIAL VENTILATION; BLEEDING; CASE STUDY; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TREATMENT FAILURE; ENZYME DEFECT; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART HEMODYNAMICS; HUMAN; HYPERTHERMIA; INFANT; KIDNEY FAILURE; LIVER FUNCTION TEST; PATENT DUCTUS ARTERIOSUS; PREMATURITY; REFERENCE VALUE; RESPIRATORY DISTRESS SYNDROME; THROMBOCYTOPENIA; TREATMENT RESPONSE; BLOOD; DUCTUS ARTERIOSUS, PATENT; INFANT, PREMATURE, DISEASES; NEWBORN;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; DUCTUS ARTERIOSUS, PATENT; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES;

EID: 84907808233     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2013.871630     Document Type: Article

References (11)

1. Zahka KG, Erenberg F. Congenital defects. In: Martin RJ, Fanaroff AA, Walsh MC, eds. Fanaroff and Martin's neonatalperinatal medicine: diseases of the fetus and infant. 9th ed. Maryland Heights (MI): Mosby; 2010: 1261-3
2. Zecca E, Romagnoli C, De Carolis M, et al. Does ibuprofen increase neonatal hyperbilirubinemia? Pediatrics 2009;124: 480-4
3. American Academy of Pediatrics, Committee on Fetus and Newborn and Section on Surgery Section on Anesthesiology and Pain Medicine, Canadian Paediatric Society, Fetus and Newborn Committee. Prevention and management of pain in the neonate: an update. Pediatrics 2006;118: 2231-41
4. Hammerman C, Bin-Nun A, Markovitch E, et al. Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics 2011;128: e1618-21
5. Oncel MY, Yurttutan S, Uras N, et al. An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants. Arch Dis Child Fetal Neonatal Ed 2013;98: F94
6. Allegaert K, Anderson B, Simons S, van Overmeire B. Paracetamol to induce ductus arteriosus closure: is it valid? Arch Dis Child 2013;98: 462-6
7. Allegaert K, Palmer GM, Anderson BJ. The pharmacokinetics of intravenous paracetamol in neonates: size matters most. Arch Dis Child 2011;96: 575-80
8. Oncel MY, Yurttutan S, Degirmencioglu H, et al. Intravenous paracetamol treatment in the management of patent ductus arteriosus in extremely low birth weight infants. Neonatology 2013;103: 166-9
9. Hammerman C. Paracetamol and patent ductus arteriosus (PDA). Clinical trials. gov identifier: NCT01291654. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01291654 [last accessed 22 Aug 2013]
10. Kluckow M. Paracetamol. Duct action (PDA) trial: the effect of paracetamol vs placebo on ductal closure in premature infants with a late patent ductus arterious. ACTRN12611000741987. Available from: https://www.anzctr.org.au/Trial/Registration/Trial Review.aspx?ACTRN'12611000741987 [last accessed 22 Aug 2013]
11. Arana A, Morton NS, Hansen TG. Treatment with paracetamol in infants. Acta Anaesthesiol Scand 2001;45: 20-9